Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged ≥ 18 years, voluntarily consented to the study.~2. WHO classification defined B-lymphoid malignancy, with the exception of Burkitt lymphoma/leukemia, plasma cell myeloma, acute lymphoblastic leukemia, lymphoblastic lymphoma, and plasmablastic lymphoma.~3. Requirement for treatment in the opinion of the investigator.~4. Disease which has relapsed, or is refractory, following at least one line of therapy, with no therapy of higher priority available.~5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.~6. Adequate hematologic function, as defined by neutrophils ≥ 1.0 x 10\^9/L and platelets ≥ 50 x 10\^9/L; participants with neutrophils \< 1.0 x 10\^9/L due to marrow infiltration are allowed to receive growth factors to bring pre-treatment neutrophils to ≥ 1.0 x 10\^9/L.~7. Adequate renal function, as defined by creatinine clearance of ≥ 30 ml/min (as estimated by the Cockcroft-Gault equation or as measured by nuclear medicine scan or 24 hour urine collection).~8. Adequate liver function, as defined by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN), and bilirubin ≤ 1.5 x ULN (unless documented Gilbert's syndrome).~9. International normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN.~10. Female participants of childbearing potential and non-sterile males must practice at least one of the following methods of birth control with partner(s) throughout the study and for 90 days after discontinuing study drug: total abstinence from sexual intercourse, double-barrier contraception, IUD or hormonal contraceptive initiated at least 3 months prior to first dose of study drug.~11. Male participants must not donate sperm from initial study drug administration, until 90 days after drug discontinuation.~Exclusion Criteria:~1. Current central nervous system (CNS) involvement by disease~2. Current histologically transformed disease.~3. Prior Bruton's tyrosine kinase (BTK) inhibitor treatment.~4. Allogeneic stem cell transplantation within 6 months, or has active graft-versus-host disease (GVHD) requiring ongoing immunosuppression.~5. Receipt of the following treatment prior to first dose of zanubrutinib: corticosteroids given with anti-neoplastic intent within 7 days, chemotherapy or radiotherapy within 2 weeks, monoclonal antibody within 4 weeks.~6. Not recovered from toxicity of any prior chemotherapy to grade ≤ 1.~7. History of other active malignancies within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally (surgery or other modality) with curative intent.~8. Uncontrolled systemic infection requiring parenteral anti-microbial therapy.~9. Major surgery in the past 4 weeks.~10. Known HIV, or active hepatitis B or hepatitis C infection (detected positive by PCR).~11. Cardiovascular disease resulting in New York Heart Association function status of ≥ 3.~12. Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease that in the investigator's opinion would adversely impact on his/her participating in the study.~13. Inability to comply with study procedures.~14. On medications which are cytochrome P450 (CYP) 3A inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zanubrutinib (Type: EXPERIMENTAL): Participants were administered up to 320 mg total daily dose of zanubrutinib until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up

Based on this trial design, predict the completion outcome and termination type (if applicable).